Routine staging endoscopic ultrasound is not required for T2-T4a oesophageal/junctional cancer
Findlay J. et al, (2013), BRITISH JOURNAL OF SURGERY, 100, 45 - 45
Unsuccessful validation of the NUn score, for predicting anastomotic leak, morbidity and mortality after oesophagectomy
Findlay J. et al, (2013), BRITISH JOURNAL OF SURGERY, 100, 46 - 47
Intravenous versus oral dexamethasone premedication in preventing Paclitaxel infusion hypersensitivity reactions in gynecological malignancies.
O'Cathail SM. et al, (2013), Int J Gynecol Cancer, 23, 1318 - 1325
ESTABLISHMENT OF LYMPHO-MYELOID RESTRICTED PROGENITORS PRIOR TO THE EMERGENCE OF DEFINITIVE HEMATOPOIETIC STEM CELLS
Boiers C. et al, (2013), EXPERIMENTAL HEMATOLOGY, 41, S13 - S13
Directed phenotype switching as an effective antimelanoma strategy.
Sáez-Ayala M. et al, (2013), Cancer Cell, 24, 105 - 119
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: A phase 2 double-blind randomised study
Robert C. et al, (2013), The Lancet Oncology, 14, 733 - 740
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C. et al, (2013), Lancet Oncol, 14, 733 - 740
FLT3-ITDs instruct a myeloid differentiation and transformation bias in lymphomyeloid multipotent progenitors.
Mead AJ. et al, (2013), Cell Rep, 3, 1766 - 1776
Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial.
Corrie P. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
A GENOMEWIDE ASSOCIATION STUDY IDENTIFIES NOVEL LOCI THAT PREDISPOSE TO MYELOPROLIFERATIVE NEOPLASMS
Jones A. et al, (2013), HAEMATOLOGICA, 98, 221 - 222
Tumour lysis syndrome in a patient with intravascular spread from a recurrent epithelial ovarian cancer
Camarata M. et al, (2013), BMJ Case Reports
Germline counterparts of oncogenic mutations: who gives a JAK?.
Mead AJ. et al, (2013), Oncotarget, 4, 814 - 815
A phase I study of oral rucaparib in combination with carboplatin.
Molife LR. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
AVAST-M: Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence.
Corrw P. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma
Gupta A. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
Ipilimumab in the real world: The UK expanded access programme (EAP) experience in advanced melanoma.
Ahmad S. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
Phase II double-blind, randomized study of selumetinib (SEL) plus dacarbazine (DTIC) versus placebo (PBO) plus DTIC as first-line treatment for advanced BRAF-mutant cutaneous or unknown primary melanoma
Middleton MR. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
Phase II trial of nemorubicin hydrochloride (N) in combination with cisplatin (cDDP) administered by intra-hepatic artery (IHA) in patients (pts) with hepatocellular carcinoma (HCC): Final results.
Izzo F. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31
Safety, pharmacokinetics, and preliminary activity of the alpha-specific PI3K inhibitor BYL719: Results from the first-in-human study.
Gonzalez-Angulo AM. et al, (2013), JOURNAL OF CLINICAL ONCOLOGY, 31